Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology)

重组人源化抗PD-L1单克隆抗体（泰州厚德奥科）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology)
Drug Alias NameLP-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaSolid tumoursSmall Cell Lung Carcinoma +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTaizhou Houde Aoke Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTaizhou Houde Aoke Technology Co Ltd
Inactive CompaniesTaizhou HoudeAoke Biomedical Co Ltd
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaDigestive System Neoplasms
Inactive IndicationsPrimary mediastinal B cell lymphomaCarcinoma, Squamous CellMelanoma

Other Information

ATC CodeN/A
Related LinksN/A